MarginsXMarginsX
Home › Markets › Health Care › LTGO

Latigo Biotherapeutics Inc. (LTGO)

LTGO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$12.60
-3.89% on the day
Market cap
$835.4M
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerLTGO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2026
SEC CIK0002056611
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
61.0 months
$401.2M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$2.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Accordingly, the prior substantial doubt about the Company's ability to continue as a going concern has been alleviated. 2."
10-Q 2026-11-05
Cash and burn$401.2M cash; operating cash flow -$19.7M a quarter.Report 2026-09-30
Shares outstanding66,299,347 (2026-11-02).Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Diego, California, United StatesPCAOB Form AP 2026-08-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $2.5M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$20.9M-$19.5M$401.2MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q3 2026
2026-06-30
Not filed-$25.8MNot filed$55.0M$64.9MNeeds four quarters10-Q 2026-11-05
Q3 2026
2026-03-31
Not filed-$23.0MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-05
Q3 2026
2025-09-30
Not filed-$24.8M-$19.9M$104.6MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q3 2026
2025-06-30
Not filed-$25.8MNot filed$74.5MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q3 2026
2025-03-31
Not filed-$21.0MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-08-07
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05

Source: SEC EDGAR submissions feed, 46 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.0%
1 month-16.5%
3 months-34.6%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-47.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RIGLRigel Pharmaceuticals Inc.$43.73-1.64%$823.4M
SNDXSyndax Pharmaceuticals Inc.$9.13-3.39%$821.6M
CTYCity Therapeutics Inc.$16.98-6.19%$854.6M
IRWDIronwood Pharmaceuticals Inc.$4.85+0.41%$802.9M
COLLCollegium Pharmaceutical Inc.$25.43+0.43%$790.2M
PHARPharming Group N.V. ADS each representing 10$12.59-0.08%$889.2M
IVAInventiva S.A. American Depository Shares$3.32-9.78%$784.5M
CRVSCorvus Pharmaceuticals Inc.$10.60-0.38%$894.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier